PHOENIX, Dec. 5, 2023
/PRNewswire/ -- Trinity Capital Inc. (NASDAQ: TRIN) ("Trinity"), a
leading provider of diversified financial solutions to growth-stage
companies, today announced the commitment of $45 million in growth capital to Neurolens, a
company commercializing innovative solutions to optimize
vision.
Neurolens offers the only prescription lenses that use a
contoured prism to treat headaches, neck and shoulder pain, and
eyestrain caused by eye misalignment. The company recently
announced the launch of the N3, a fast and accurate way for eyecare
providers to measure eye misalignment down to a fraction of a prism
diopter. The company is committed to enhancing patient outcomes and
assisting eye care providers in delivering much-needed relief to
their patients.
"With the introduction of the N3, Neurolens will enable even
more eye care professionals to access contoured prism technology in
their optometry practices," said Igor
DaCruz, Managing Director, Life Sciences at Trinity. "We are
thrilled to work with them as they continue changing the lives of
patients."
This capital will fuel continued growth in the company's
operations and is expected to further accelerate the adoption of
Neurolens N3 devices in optometry practices across the United States and Canada.
"While we continue to experience double-digit growth each year,
the unmet patient need remains immense," said Davis Corley, Executive Chairman of Neurolens.
"We are committed to leveraging innovative technology like the N3
to remove barriers to adoption and ensure that every eye care
professional can access these life-changing outcomes for their
patients. We are grateful that Trinity Capital Inc.—along with our
dedicated investors—are embracing our mission to transform eye
care."
About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN), an internally managed
business development company, is a leading provider of diversified
financial solutions to growth-stage companies with institutional
equity investors. Trinity Capital's investment objective
is to generate current income and, to a lesser extent, capital
appreciation through investments, including term loans and
equipment financings and equity-related investments. Trinity
Capital believes it is one of only a select group of specialty
lenders that has the depth of knowledge, experience and track
record in lending to growth stage companies. For more information,
please visit the Company's website at www.trinitycap.com.
About Neurolens
Neurolens commercializes breakthrough
technology to improve vision care. With patented Contoured Prism
technology, Neurolenses are the first and only prescription lenses
that go beyond visual acuity to provide comfort for the majority of
adults who complain of headaches, neck/shoulder pain and eyestrain
when using digital devices, reading or doing detail work. The
Neurolens Contoured Prism design helps the eyes work together
comfortably, bringing the eyes into alignment to relieve painful
symptoms. Technology from Neurolens is only available to
Independent Eye Care Providers. To learn more about Neurolens,
please visit our website at https://www.neurolens.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-45-million-growth-capital-to-neurolens-302005218.html
SOURCE Trinity Capital Inc.